AstraZeneca’s Dapagliflozin gets additional indication approval for heart failure treatment in India07/25/2023 majac Heart Disease The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca.Share on FacebookTweetFollow usSave